Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: three on the market, one awaiting approval, four in clinical trials and three in research and development. The company’s products treat a wide range of diseases and conditions, including malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration.
Sinobiomed explains its technology like this: “The process of discovering a new drug involves determining which proteins cause or contribute to problems in the body because they are lacking, malfunctioning or present in too great numbers and then identifying and engineering a protein or related molecule to correct the problem. Recombinant DNA technology is the process of removing DNA from one organism and placing it into a new organism that reproduces to make proteins of potential therapeutic value. This technology is at the foundation of biotechnology and Sinobiomed.
“Recombinant protein drugs and other bio-products have three main advantages over traditional chemical pharmaceuticals: their safety, low-cost and efficacy. Because recombinant protein drugs and other biopharmaceuticals are made from human components, such as proteins, enzymes and hormones, they have a built in safety factor. Procedures and processes for developing and purifying these recombined proteins are stringently quality controlled and highly effective and result in products with guaranteed purity of 95% or higher. Sinobiomed uses a patented process that is extremely efficient at purifying recombinant proteins at low cost — and in producing recombinant proteins that are highly efficacious.”
Let us hear your thoughts: Sinobiomed Inc. Message Board